Researcher: Demirel, Çağrı
Name Variants
Demirel, Çağrı
Email Address
Birth Date
2 results
Search Results
Now showing 1 - 2 of 2
Publication Metadata only Can incidental vascular calcifications at mammography be used as a screening biomarker for heart and kidney disease?(Sage, 2019) Covic, Adrian; A. Sag, Alan; Afsar, Barış; N/A; Erbil, Damla; Önal, Emine Meltem; Demirel, Çağrı; Dağel, Tuncay; Kanbay, Mehmet; Undergraduate Student; Undergraduate Student; Undergraduate Student; Doctor; Faculty Member; School of Medicine; School of Medicine; School of Medicine; N/A; School of Medicine; Koç University Hospital; N/A; N/A; N/A; N/A; 110580Mammography is a screening test with extensive international application and financial infrastructure promoting accessibility and affordability. Designed specifically to detect microcalcifications, mammography is powered to detect calcifications in vessel walls. Breast arterial calcifications (BAC) are one of the most common incidental findings documented by mammography. This review considers the literature regarding BAC in relation to cardiovascular disease (CVD) and its risk factors. The aim is to assess the possibility of using BAC as an early surrogate imaging biomarker of CVD.Publication Metadata only GLP-1’s role in neuroprotection: a systematic review(Taylor & Francis Ltd, 2019) N/A; N/A; N/A; N/A; Erbil, Damla; Eren, Candan Yasemin; Demirel, Çağrı; Küçüker, Mehmet Utku; Solaroğlu, İhsan; Eser, Hale Yapıcı; Undergraduate Student; PhD Student; Undergraduate Student; Researcher; Faculty Member; Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM); School of Medicine; Graduate School of Health Sciences; School of Medicine; School of Medicine; School of Medicine; N/A; N/A; N/A; N/A; 102059; 134359Glucagon-like peptide 1 (GLP-1) is a target for treatment of diabetes; however, its function in the brain is not well studied. In this systematic review, we aimed to analyze the neuroprotective role of GLP-1 and its defined mechanisms.Methods: We searched Web of Science' and Pubmed' to identify relevant studies using GLP-1 as the keyword. Two hundred and eighty-nine clinical and preclinical studies have been included. Data have been presented by grouping neurodegenerative, neurovascular and specific cell culture models.Results: Recent literature shows that GLP-1 and its agonists, DPP-4 inhibitors and combined GLP-1/GIP molecules are effective in partially or fully reversing the effects of neurotoxic compounds, neurovascular complications of diabetes, neuropathological changes related with Alzheimer's disease, Parkinson's disease or vascular occlusion. Possible mechanisms that provide neuroprotection are enhancing the viability of the neurons and restoring neurite outgrowth by increased neurotrophic factors, increasing subventricular zone progenitor cells, decreasing apoptosis, decreasing the level of pro-inflammatory factors, and strengthening blood-brain barrier.Conclusion: Based on the preclinical studies, GLP-1 modifying agents are promising targets for neuroprotection. On the other hand, the number of clinical studies that investigate GLP-1 as a treatment is low and further clinical trials are needed for a benchside to bedside translation of recent findings.